Please assess the completion status of the following clinical trial:

Trial Title: Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for participation in this study, subjects must meet all of the following criteria:~* have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.~* be prior to initiation of or between cycles of chemotherapy.~* have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)~  % weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%~* If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.~* have a life expectancy of \>6 months~* FEMALES - be clinically confirmed as postmenopausal~* MALES - over 45 years of age~* ECOG score ≤1~Exclusion Criteria:~Subjects with any of the following will NOT be eligible for enrollment in this study:~* history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection~* Cardiovascular: No uncontrolled hypertension~* Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV~* Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)~* Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1 mg GTx-024
- 2 (Type: EXPERIMENTAL): 3 mg GTx-024
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).